Qva149 Significantly Lowers The Rate And Risk Of Moderate Or Severe COPD Exacerbation Versus Salmeterol/fluticasone In Patients With Moderate To Severe COPD: The Lantern Study

被引：0
|
作者：
Zhong, N. [1 ]
Wang, C. [2 ]
Zhou, X. [3 ]
Zhang, N. [1 ]
Patalano, F. [4 ]
Humphries, M. [5 ]
Wang, L. [5 ]
Banerji, D. [6 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China
[2] Third Mil Med Univ, Inst Resp Dis, Xin Qiao Hosp, Chongqing, Peoples R China
[3] Third Mil Med Univ, Southwest Hosp, Dept Resp Med, Chongqing, Peoples R China
[4] Novartis Pharma AG, Basel, Switzerland
[5] Beijing Novartis Pharma Co Ltd, Shanghai, Peoples R China
[6] Novartis Pharmaceut, E Hanover, NJ USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2015年 / 191卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3978
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations
    Banerji, Donald
    Patalano, Francesco
    RESPIRATORY MEDICINE, 2016, 110 : 79 - 80
  • [42] Risk factors for cardiovascular disease in patients with COPD: mild-to-moderate COPD versus severe-to-very severe COPD
    de Oliveira Caram, Laura Miranda
    Ferrari, Renata
    Naves, Cristiane Roberta
    Coelho, Liana Sousa
    do Vale, Simone Alves
    Tanni, Suzana Erico
    Godoy, Irma
    JORNAL BRASILEIRO DE PNEUMOLOGIA, 2016, 42 (03) : 179 - 184
  • [43] Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations
    Donohue, James F.
    Worsley, Sally
    Zhu, Chang-Qing
    Hardaker, Liz
    Church, Alison
    RESPIRATORY MEDICINE, 2015, 109 (07) : 870 - 881
  • [44] QVA149 Improves Lung Function and Reduces Exacerbations Compared With Tiotropium in Patients With Severe-to-Very Severe COPD: The SPARK Study
    Ficker, Joachim
    Wedzicha, Jadwiga
    FowlerTaylor, Angel
    D'Andrea, Peter
    Arrasate, Christie
    Chen, Hungta
    Banerji, Donald
    CHEST, 2014, 145 (03)
  • [45] Sputum microbiota in moderate versus severe patients with COPD
    Galiana, Antonio
    Aguirre, Estefania
    Rodriguez, Juan Carlos
    Mira, Alex
    Santibanez, Miguel
    Candela, Inmaculada
    Llavero, Juana
    Garcinuno, Pedro
    Lopez, Francisco
    Ruiz, Montserrat
    Garcia-Pachon, Eduardo
    Royo, Gloria
    EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (06) : 1787 - 1790
  • [46] QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
    Ficker, Joachim H.
    Wedzicha, Jadwiga A.
    Decramer, Marc
    FowlerTaylor, Angel
    D'Andrea, Peter
    Arrasate, Christie
    Chen, Hungta
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [47] EFFECT OF INDACATEROL/GLYCOPYRRONIUM ON THE TIME TO FIRST MODERATE OR SEVERE COPD EXACERBATION VERSUS SALMETEROL/FLUTICASONE BY BASELINE BLOOD EOSINOPHIL LEVELS: FINDINGS FROM THE FLAME STUDY
    Wedzicha, J. A.
    Vogelmeier, C.
    Larbig, M.
    Patalano, F.
    Thach, C.
    Fogel, R.
    Banerji, D.
    RESPIROLOGY, 2016, 21 : 117 - 117
  • [48] Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study
    Mahler, Donald A.
    Decramer, Marc
    D'Urzo, Anthony
    Worth, Heinrich
    White, Tracy
    Alagappan, Vijay
    Chen, Hungta
    Kulich, Karoly
    Gallagher, Nicola
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [49] ONCE-DAILY QVA149 PROVIDES SUPERIOR BRONCHODILATION AND IMPROVES LUNG FUNCTION VERSUS TWICE-DAILY FLUTICASONE/SALMETEROL IN COPD PATIENTS: THE ILLUMINATE STUDY
    Vogelmeier, C.
    Bateman, E.
    Pallante, J.
    Bryant, H.
    Alagappan, V.
    D'Andrea, P.
    He, E.
    Banerji, D.
    THORAX, 2012, 67 : A149 - A149
  • [50] Once-Daily QVA149 Demonstrates Superior Improvements in Patient-Reported Dyspnea Compared to Tiotropium in Patients With Moderate-to-Severe COPD: The BLAZE Study
    D'Urzo, Anthony
    Mahler, Donald
    Worth, Heinrich
    White, Tracy
    Alagappan, Vijay
    Chen, Hungta
    Kulich, Karoly
    Gallagher, Nicola
    Banerji, Donald
    CHEST, 2014, 145 (03)
12345